Corey Ostman
Corey Ostman
bottom exact price
Exact did have to price at bottom of the range, but at least they didn't have to cut.
among brand decent demand developing seem
The interesting thing is that they seem to be developing pretty decent brand recognition among consumers. It does show that there is some demand for more non-infrastructure issues.
general
After the genomic (breakthrough) biotech in general has been doing really well.
hearing interested moderate reasonably sorts
Institutions are always interested in hearing about these sorts of deal. They could do reasonably well and see a moderate pop.
dynamics great hard hype invest predict
The dynamics of an IPO, especially one with the hype like this one, is always hard to predict right out of the gate. But this is a great company. It's one a lot of institutions are going to want to invest in.
cautious market perfect shaky trade
The market is so cautious right now and so shaky that if you don't have all those perfect scenarios, then you will trade at your IPO price.
company expect looking main stay
The main thing I'm looking at is I expect this to stay on the calendar. If it were a high-tech company it would be up in the air.
best capital consulting deal firm human instead market people perspective profitable sector value
The human capital sector is very hot. But . . . the market may value this deal as a consulting firm instead of a human capital firm. That's just not the best sector right now. People have the perspective that it's not the most profitable industry.
company deals decent market revenue sort tech
The market for tech deals is sort of on-again, off-again, so you've got to look at the fundamentals that they have decent revenue for a company this size.